CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Phase 2 Terminated
63 enrolled 11 charts
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Phase 1 Terminated
35 enrolled 10 charts
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Phase 2 Terminated
13 enrolled 9 charts
iinnovate-3
Phase 1/2 Terminated
15 enrolled 12 charts
iinnovate-1
Phase 1/2 Terminated
272 enrolled 67 charts
iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
TOMMY
Phase NA Terminated
13 enrolled 10 charts
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
15 enrolled 15 charts
LIMBER
Phase 1/2 Terminated
22 enrolled 28 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Phase 2 Terminated
24 enrolled 8 charts
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Phase 2 Terminated
17 enrolled 9 charts
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Phase NA Terminated
2,117 enrolled 6 charts
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
141 enrolled 46 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Terminated
13 enrolled 10 charts
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
20 enrolled 12 charts
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
36 enrolled 17 charts
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
10 enrolled 14 charts
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Phase 2 Terminated
88 enrolled 21 charts
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Phase 1/2 Terminated
103 enrolled 21 charts
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Phase 2 Terminated
15 enrolled 12 charts
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
Phase 1/2 Terminated
4 enrolled 16 charts
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Phase 2 Terminated
1 enrolled 14 charts
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Terminated
4,253 enrolled 21 charts
EMBRACE
Phase 2 Terminated
1 enrolled 5 charts
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
Phase NA Terminated
12 enrolled 18 charts
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Phase 2 Terminated
3 enrolled 5 charts
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Phase 1 Terminated
83 enrolled 57 charts
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Phase 2 Terminated
13 enrolled 9 charts
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
19 enrolled 22 charts
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Phase 1/2 Terminated
23 enrolled 13 charts
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
17 enrolled 10 charts
Precision Medicine for Patients With Identified Actionable Mutations
Phase 2 Terminated
45 enrolled 13 charts
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
6 enrolled 10 charts
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Phase 2 Terminated
5 enrolled 12 charts
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase 1/2 Terminated
9 enrolled 13 charts
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Phase 1/2 Terminated
105 enrolled 16 charts
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Phase 2 Terminated
8 enrolled 8 charts
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
Phase 1/2 Terminated
9 enrolled 14 charts
OCEAN
Phase 3 Terminated
495 enrolled 15 charts
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Phase 2 Terminated
9 enrolled 9 charts
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
Phase 3 Terminated
16 enrolled 7 charts
ClaSPd
Phase 2 Terminated
4 enrolled 9 charts
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
17 enrolled 15 charts
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase 1/2 Terminated
32 enrolled 18 charts
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 9 charts
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
Phase 1/2 Terminated
11 enrolled 11 charts